XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.4
Document And Entity Information - USD ($)
$ in Millions
 12 Months Ended
Sep. 30, 2024
Dec. 18, 2024
Mar. 28, 2024
Document Information Line Items      
Entity Central Index Key 0001506251    
Document Type 10-K/A    
Document Annual Report true    
Current Fiscal Year End Date --09-30    
Document Period End Date Sep. 30, 2024    
Document Fiscal Year Focus 2024    
Document Transition Report false    
Entity File Number 001-38174    
Entity Registrant Name Citius Pharmaceuticals, Inc.    
Entity Incorporation, State or Country Code NV    
Entity Tax Identification Number 27-3425913    
Entity Address, Address Line One 11 Commerce Drive    
Entity Address, Address Line Two First Floor    
Entity Address, City or Town Cranford    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07016    
City Area Code (908)    
Local Phone Number 967-6677    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Trading Symbol CTXR    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 131,670,000
Entity Common Stock, Shares Outstanding   7,727,243  
Amendment Description This Amendment No. 1 to Form 10-K (this “Form 10-K/A”) amends the Annual Report on Form 10-K of Citius Pharmaceuticals, Inc., a Nevada corporation (the “Company,” “we,” “us,” and “our,” as applicable), for the year ended September 30, 2024, that we originally filed with the Securities and Exchange Commission (the “SEC”) on December 27, 2024 (the “Original Filing”). We are filing this Form 10-K/A for the sole purpose of including Exhibit 97.1.Pursuant to the rules of the SEC, Part IV, Item 15 (Exhibit Index) has also been amended to contain the currently dated certifications from our principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. The certifications of our principal executive officer and principal financial officer are attached to this Form 10-K/A as Exhibits 31.3 and 31.4, respectively. Because no financial statements have been included in this Form 10-K/A and this Form 10-K/A does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, we have omitted paragraphs 3, 4 and 5 of the certifications filed with this Form 10-K/A. Additionally, we are not including the certifications under Section 906 of the Sarbanes-Oxley Act of 2002, because we are not filing any financial statements with this Form 10-K/A.Except as set forth in this Form 10-K/A, this Form 10-K/A does not amend or otherwise update any other information in the Original Filing. Other than the information specifically amended and restated herein, this Form 10-K/A does not reflect events occurring after December 27, 2024, the date of the Original Filing, or modify or update those disclosures that may have been affected by subsequent events. Accordingly, this Form 10-K/A should be read in conjunction with the Original Filing and with our filings with the SEC after the Original Filing.    
Amendment Flag true    
Document Fiscal Period Focus FY